Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer



Status:Recruiting
Conditions:Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:September 2014
End Date:July 2017

Use our guide to learn which trials are right for you!

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy

The purpose of this study is to evaluate the efficacy and safety of aldoxorubicin compared
to topotecan in subjects with metastatic small cell lung cancer.


Inclusion Criteria:

1. Age ≥18 years male or female.

2. Histological confirmation of SCLC.

3. Relapsed or refractory to no more than 1 course of a systemic therapy regimen and is
incurable by either surgery or radiation.

4. Capable of providing informed consent and complying with trial procedures.

5. ECOG PS 0-2.

6. Life expectancy >8 weeks.

7. Measurable tumor lesions according to RECIST 1.1 criteria.[22]

8. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,
surgically sterile, or practicing adequate birth control methods) for the duration of
the study. (Adequate contraception includes: oral contraception, implanted
contraception, intrauterine device implanted for at least 3 months, or barrier method
in conjunction with spermicide.)

9. Males and their female partner(s) of child-bearing potential must use 2 forms of
effective contraception (see Inclusion 8 plus condom or vasectomy for males) from the
last menstrual period of the female partner during the study treatment and for 6
months after the final dose of study treatment.

10. Women of child bearing potential must have a negative serum or urine pregnancy test
at the Screening Visit and be non-lactating.

11. Accessibility to the site that ensures the subject will be able to keep all
study-related appointments.

Exclusion Criteria:

1. Prior exposure to >375 mg/m2 of doxorubicin or liposomal doxorubicin.

2. Prior treatment with topotecan.

3. Palliative surgery and/or radiation treatment < 21 days prior to date of
randomization.

4. Exposure to any investigational agent within 30 days of date of randomization.

5. Exposure to any systemic chemotherapy within 21 days of date of randomization.

6. Active (symptomatic) central nervous system (CNS) metastasis.

7. History of other malignancies except cured basal cell carcinoma, cutaneous squamous
cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of
the cervix unless documented free of cancer for ≥3 years.

8. Laboratory values: Screening serum creatinine >1.5×upper limit of normal (ULN),
alanine aminotransferase (ALT) >3×ULN or >5×ULN if liver metastases are present,
total bilirubin >2×ULN, absolute neutrophil count (ANC) <1,500/mm3, platelet
concentration <100,000/mm3, hemoglobin <9 g/dL, albumin <2 gm/dL.

9. Anion gap > 16 meq/L or arterial blood pH < 7.30.

10. Clinically evident congestive heart failure (CHF) > class II of the New York Heart
Association (NYHA) guidelines (Appendix D).

11. Current, serious, clinically significant cardiac arrhythmias, defined as the
existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown
III, IV or V (Appendix F).

12. Baseline QTc >470 msec measured by Fridericia's formula (QTcF) and/or previous
history of QT prolongation while taking other medications. Concomitant use of
medications associated with a high incidence of QT prolongation is not allowed.

13. History or signs of active coronary artery disease with angina pectoris within the
last 6 months.

14. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection
fraction (LVEF) below the institution's lower limit of predicted normal.

15. Known history of HIV infection.

16. Active, clinically significant serious infection requiring treatment with
antibiotics, anti-virals or anti-fungals.

17. Treatment with p-glycoprotein inhibitors such as cyclosporine A, elacridar,
ketoconazole, ritonavir, saquinavir.

18. Major surgery within 30 days prior to date of randomization.

19. Substance abuse or any condition that might interfere with the subject's
participation in the study or in the evaluation of the study results.

20. Any condition that is unstable and could jeopardize the subject's participation in
the study.
We found this trial at
20
sites
Knoxville, Tennessee 37920
Principal Investigator: Russel DeVore, M.D.
Phone: 865-934-2672
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Alain Mita, M.D.
Phone: 910-423-2276
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Boca Raton, Florida 33486
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Budapest,
Principal Investigator: Katalin Udud, M.D.
Phone: +36 (1) 391 3233
?
mi
from
Budapest,
Click here to add this to my saved trials
Cattanooga, Tennessee 37404
Principal Investigator: Davey Daniel, M.D.
Phone: 877-691-7274
?
mi
from
Cattanooga, TN
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: David Waterhouse, M.D.
Phone: 877-691-7274
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Easton, Maryland 21601
?
mi
from
Easton, MD
Click here to add this to my saved trials
Fleming Island, Florida 32003
Principal Investigator: Augusto Villegas, M.D.
Phone: 904-538-4488
?
mi
from
Fleming Island, FL
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Principal Investigator: Chandra Belani, M.D.
Phone: 772-408-5158
?
mi
from
Hershey, PA
Click here to add this to my saved trials
529 S Jackson St
Louisville, Kentucky 40202
(502) 562-4369
Principal Investigator: Goetz Kloecker, M.D.
Phone: 502-562-3429
James Graham Brown Cancer Center No one should feel compelled to leave Kentucky to seek...
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Marietta, Georgia 30060
Principal Investigator: Robert Hermann, M.D.
Phone: 770-281-5131
?
mi
from
Marietta, GA
Click here to add this to my saved trials
?
mi
from
Marrero, LA
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Principal Investigator: Ray Page, M.D.
Phone: 615-524-4032
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Pasadena, California 91105
Principal Investigator: Marianna Koczywas, M.D.
Phone: 626-256-4673
?
mi
from
Pasadena, CA
Click here to add this to my saved trials
Port St. Lucie, Florida 34982
?
mi
from
Port St. Lucie, FL
Click here to add this to my saved trials
Portland, Oregon 97227
Principal Investigator: Abdul Hai Mansoor, M.D
Phone: 503-331-6537
?
mi
from
Portland, OR
Click here to add this to my saved trials
St. Louis, Missouri 63110
Principal Investigator: Maria Baggstrom, M.D.
Phone: 314-362-4140
?
mi
from
St. Louis, MO
Click here to add this to my saved trials